A Randomized, Open-Label Clinical Study to Assess the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine When Administered Concomitantly With RotaTeq or Rotarix in Healthy Infants in South Africa.

Trial Profile

A Randomized, Open-Label Clinical Study to Assess the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine When Administered Concomitantly With RotaTeq or Rotarix in Healthy Infants in South Africa.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2013

At a glance

  • Drugs DTaP vaccine; DTaP-hepatitis B vaccine; RIX 4414; Rotavirus W179-9 vaccine
  • Indications Diphtheria; Hepatitis B; Pertussis; Rotavirus infections; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Merck & Co
  • Most Recent Events

    • 06 Feb 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 06 Feb 2010 Actual initiation date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 06 Feb 2010 Planned end date changed from 1 Aug 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top